Therefore, we selected DTA as a therapeutic gene for gene therapy of these heterogeneous tumors to inhibit protein synthesis, which has been used in various cancers [32,33,34,35,36,37,38,39,40,41,42,43,44], and used an AFP promoter to control its expression within the AFP-expressing HCC cells. The gene discussed is AFP; the disease is hepatocellular carcinoma.